CPRC
VRTX icon

Consolidated Portfolio Review Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,002
Closed -$392K – 414
2025
Q3 		$392K Buy
+1,002
New +$419K 0.05% 313

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Consolidated Portfolio Review Corp's VRTX Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 1,002 shares — an estimated $392K sold.

Consolidated Portfolio Review Corp first reported a position in VRTX in Q3 2025 and held it in 1 quarter. The position peaked at $392K in Q3 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 1,002 Vertex Pharmaceuticals shares in Q4 2025, an estimated $392K.
  • Consolidated Portfolio Review Corp first reported a position in Vertex Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Consolidated Portfolio Review Corp's Vertex Pharmaceuticals position peaked at $392K in Q3 2025.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.